July 5, 2017 / 11:16 AM / 21 days ago

BRIEF-Beigene initiates pivotal trial of PD-1 antibody BGB-a317 in China

1 Min Read

July 5 (Reuters) - Beigene Ltd

* Beigene initiates pivotal trial of PD-1 antibody BGB-a317 in China in patients with urothelial cancer

* Beigene Ltd - plan to expand development program for BGB-A317 in China and other geographies, both as monotherapy and in combination

* Beigene - ‍trial's primary endpoint is ORR according to response evaluation criteria in solid tumors version 1.1 as assessed by independent review​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below